-
1
-
-
84887153834
-
Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication
-
for the SMART Study Group
-
A.P. van de Woestijne, Y. van der Graaf, A.-H. Liem, M.J.M. Cramer, J. Westerink, F.L.J. Visseren for the SMART Study Group Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication J Am Coll Cardiol 62 2013 1834 1841
-
(2013)
J Am Coll Cardiol
, vol.62
, pp. 1834-1841
-
-
Van De Woestijne, A.P.1
Van Der Graaf, Y.2
Liem, A.-H.3
Cramer, M.J.M.4
Westerink, J.5
Visseren, F.L.J.6
-
2
-
-
77955712458
-
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: An analysis from the JUPITER trial
-
P.M. Ridker, J. Genest, and S.M. Boekholdt HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial Lancet 376 2010 333 339
-
(2010)
Lancet
, vol.376
, pp. 333-339
-
-
Ridker, P.M.1
Genest, J.2
Boekholdt, S.M.3
-
3
-
-
34748887666
-
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
-
for the Treating to New Targets Investigators
-
P. Barter, A.M. Gotto, J.C. LaRosa for the Treating to New Targets Investigators HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310
-
(2007)
N Engl J Med
, vol.357
, pp. 1301-1310
-
-
Barter, P.1
Gotto, A.M.2
Larosa, J.C.3
-
4
-
-
61549120401
-
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: Results from PROVE IT-TIMI 22
-
the TIMI Study Group
-
K.K. Ray, C.P. Cannon, R. Cairns, D.A. Morrow, P.M. Ridker, E. Braunwald the TIMI Study Group Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22 Arterioscler Thromb Vasc Biol 29 2009 424 430
-
(2009)
Arterioscler Thromb Vasc Biol
, vol.29
, pp. 424-430
-
-
Ray, K.K.1
Cannon, C.P.2
Cairns, R.3
Morrow, D.A.4
Ridker, P.M.5
Braunwald, E.6
-
5
-
-
84887150818
-
Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)
-
S. Acharjee, W.E. Boden, and P.M. Hartigan Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post-hoc analysis from the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) J Am Coll Cardiol 62 2013 1826 1833
-
(2013)
J Am Coll Cardiol
, vol.62
, pp. 1826-1833
-
-
Acharjee, S.1
Boden, W.E.2
Hartigan, P.M.3
-
6
-
-
70450081001
-
Major lipids, apolipoproteins, and risk of vascular disease
-
for the Emerging Risk Factors Collaboration
-
E. Di Angelantonio, N. Sarwar, P. Perry for the Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
-
(2009)
JAMA
, vol.302
, pp. 1993-2000
-
-
Di Angelantonio, E.1
Sarwar, N.2
Perry, P.3
-
7
-
-
44649140474
-
Association of loss-of-function mutations in the ABCA1 gene with HDL-C levels and risk of IHD
-
R. Frikke-Schmidt, B.G. Nordestgaard, and M.C. Stene Association of loss-of-function mutations in the ABCA1 gene with HDL-C levels and risk of IHD JAMA 299 2008 2524 2532
-
(2008)
JAMA
, vol.299
, pp. 2524-2532
-
-
Frikke-Schmidt, R.1
Nordestgaard, B.G.2
Stene, M.C.3
-
8
-
-
84856786437
-
LCAT, HDL cholesterol and ischemic cardiovascular disease: A Mendelian randomization study of HDL cholesterol in 54,500 individuals
-
C.L. Haase, A. Tybjærg-Hansen, A.A. Qayyum, J. Schou, B.G. Nordestgaard, and R. Frikke-Schmidt LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals J Clin Endocrinol Metab 97 2012 E248 E256
-
(2012)
J Clin Endocrinol Metab
, vol.97
-
-
Haase, C.L.1
Tybjærg-Hansen, A.2
Qayyum, A.A.3
Schou, J.4
Nordestgaard, B.G.5
Frikke-Schmidt, R.6
-
9
-
-
84864845456
-
Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study
-
B.F. Voight, G.M. Peloso, and M. Orho-Melander Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study Lancet 380 2012 572 580
-
(2012)
Lancet
, vol.380
, pp. 572-580
-
-
Voight, B.F.1
Peloso, G.M.2
Orho-Melander, M.3
-
10
-
-
84874900480
-
HDL-C, clinical equipoise and vascular endothelial function. Expert reviews in cardiovascular diseases
-
S. Campbell, and J. Genest HDL-C, clinical equipoise and vascular endothelial function. Expert reviews in cardiovascular diseases Expert Rev Cardiovasc Ther 11 2013 343 353
-
(2013)
Expert Rev Cardiovasc Ther
, vol.11
, pp. 343-353
-
-
Campbell, S.1
Genest, J.2
-
11
-
-
77952708442
-
Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis
-
M. Jun, B. Zhu, and M. Tonelli Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
-
(2010)
Lancet
, vol.375
, pp. 1875-1884
-
-
Jun, M.1
Zhu, B.2
Tonelli, M.3
-
12
-
-
84870045994
-
Effects of dalcetrapib in patients with a recent acute coronary syndrome
-
for the dal-OUTCOMES Investigators
-
G.G. Schwartz, A.G. Olsson, M. Abt for the dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
-
(2012)
N Engl J Med
, vol.367
, pp. 2089-2099
-
-
Schwartz, G.G.1
Olsson, A.G.2
Abt, M.3
-
13
-
-
84855171302
-
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
-
for the AIM-HIGH Investigators
-
W.E. Boden, J.L. Probstfield, T. Anderson for the AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
-
(2011)
N Engl J Med
, vol.365
, pp. 2255-2267
-
-
Boden, W.E.1
Probstfield, J.L.2
Anderson, T.3
-
14
-
-
84877299845
-
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
-
HPS2-THRIVE Collaborative Group
-
HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
-
(2013)
Eur Heart J
, vol.34
, pp. 1279-1291
-
-
-
15
-
-
78651379500
-
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
-
A.V. Khera, M. Cuchel, and M. de la Llera-Moya Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
-
(2011)
N Engl J Med
, vol.364
, pp. 127-135
-
-
Khera, A.V.1
Cuchel, M.2
De La Llera-Moya, M.3
-
16
-
-
79959919890
-
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease
-
C. Besler, K. Heinrich, and L. Rohrer Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease J Clin Invest 121 2011 2693 2708
-
(2011)
J Clin Invest
, vol.121
, pp. 2693-2708
-
-
Besler, C.1
Heinrich, K.2
Rohrer, L.3
-
17
-
-
84859384527
-
Molecular mechanisms of vascular effects of high-density lipoprotein: Alterations in cardiovascular disease
-
C. Besler, T.F. Lüscher, and U. Landmesser Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease EMBO Mol Med 4 2012 251 268
-
(2012)
EMBO Mol Med
, vol.4
, pp. 251-268
-
-
Besler, C.1
Lüscher, T.F.2
Landmesser, U.3
-
18
-
-
79955677017
-
S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease
-
K.M. Argraves, A.A. Sethi, and P.J. Gazzolo S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease Lipids Health Dis 10 2011 70 82
-
(2011)
Lipids Health Dis
, vol.10
, pp. 70-82
-
-
Argraves, K.M.1
Sethi, A.A.2
Gazzolo, P.J.3
-
20
-
-
33847368173
-
Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL
-
T. Vaisar, S. Pennathur, and P.S. Green Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL J Clin Invest 117 2007 746 756
-
(2007)
J Clin Invest
, vol.117
, pp. 746-756
-
-
Vaisar, T.1
Pennathur, S.2
Green, P.S.3
-
21
-
-
84857637772
-
HDL proteomics in acute coronary syndromes
-
K. Alwaili, D. Bailey, Z. Awan, S. Laboissiere, L. Krimbou, and J. Genest HDL proteomics in acute coronary syndromes BBA Mol Cell Biol L 1821 2012 405 415
-
(2012)
BBA Mol Cell Biol L
, vol.1821
, pp. 405-415
-
-
Alwaili, K.1
Bailey, D.2
Awan, Z.3
Laboissiere, S.4
Krimbou, L.5
Genest, J.6
-
22
-
-
84872712625
-
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult
-
T.J. Anderson, J. Grégoire, and R.A. Hegele 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult Can J Cardiol 29 2013 151 167
-
(2013)
Can J Cardiol
, vol.29
, pp. 151-167
-
-
Anderson, T.J.1
Grégoire, J.2
Hegele, R.A.3
-
23
-
-
79955476272
-
Novel HDL-directed pharmacotherapeutic strategies
-
E.M. Degoma, and D.J. Rader Novel HDL-directed pharmacotherapeutic strategies Nat Rev Cardiol 8 2011 266 277
-
(2011)
Nat Rev Cardiol
, vol.8
, pp. 266-277
-
-
Degoma, E.M.1
Rader, D.J.2
|